Long-term outcomes of percutaneous coronary intervention for unprotected left main coronary artery disease: Initial clinical experience.

C.GRAIDIS, <u>D.DIMITRIADIS</u>, V.PSIFOS, V.KARASAVVIDIS, G. TSONIS, O.HALVATZOULIS

EUROMEDICA – KYANOUS STAVROS HOSPITAL THESSALONIKI, GREECE

90 PANHELLENIC CONGRESS Of Hellenic Society of Thoracic and Cardiovascular Surgeons
Thessaloniki 23-24 November 2012



INTRODUCTION

- •Significant stenosis of the unprotected left main stem (ULM) has a worse prognosis than any other form of coronary artery disease.
- •Surgical data from the 1970s and 1980s demonstrated that bypass surgery for LM disease dramatically reduced mortality as compared with medical therapy (68% and 33% relative mortality reduction at 5 and 10 years post bypass). This clearly established bypass surgery as the gold-standard treatment for LM coronary disease.
- •The excellent results obtained with DES suggest that these devices can be an effective and safe alternative to CABG when treating left main disease in cases with anatomy suitable for percutaneous intervention



Objectives

This study aims to evaluate the clinical outcome of patients undergoing PCI to ULMCA disease in a regional hospital.



METHODS

- •Of 1,376 PCI procedures performed in our institution from January 2007 to February 2011, 52(2.9%) consecutive patients receiving unprotected LMCA intervention were identified using a prospective database.
- •Unprotected LMCA stenosis was defined as >50% diameter stenosis without patent graft to left anterior descending artery (LAD) or left circumflex artery (LCX), nor established collaterals from right coronary artery (RCA).
- •The decision for PCI over other modalities is based on surgical risk, and/or patient/physician preference.



Demographic and Clinical data (n=52)					
Age (yrs)	64,4 1 ± 3,5				
Male	42 (80.7%)				
DM	10 (19.2%)				
Arterial hypertension	22 (53.8%)				
Hypercholesterolemia	23 (44.2%)				
Smoking	28 (53.8%)				
COPD	4 (7.7%)				
Peripheral artery disease	3 (5.7%)				
Previous MI	8 (15.3%)				
Previous PCI	12 (23.1%)				
Previous CABG	4 (7.7%)				
History of stroke	2 (3.8%)				
Left ventricular ejection fraction <40%	12 (23.1%)				
NSTE-ACS	27 (51.9%)				
STEMI	3 (5.8%)				



Angiograph	nic data (n=52)
Isolated LM	16 (30.8%)
LM with 1-vessel disease	29 (55.8%)
LM with 2-vessel disease	6 (11.5%)
LM with 3-vessel disease	1 (1.9%)
Ostium involvement	14 (26.9%)
Shaft involvement	2 (3.9%)
Distal LM involvement	36 (69.2%)
Right coronary artery involvement	16 (30.7%)
No. of diseased vessels treated per	1.6 <u>+</u> 0.66
patient	
Mean Syntax Score	21,49 <u>+</u> 10,47
SS <u><</u> 22	37 (71.1%)
SS >22 and <33	8 (15.4%)
SS <u>≥</u> 33	7 (13.5%)




Procedural data (n=52)					
Mean number of vessels treated per patient (range)	1.6 <u>+</u> 0.6				
Mean number of lesion treated per patient (range)	1.98 <u>+</u> 0.81				
Mean number of stents per patient	2.26 <u>+</u> 1.38				
Mean stent length per patient (mm)	43.74 <u>+</u> 30.85				
Post-Dilatation (%)	100%				
Single stent in distal LM	30 (83.4%)				
Kissing post-dilation of distal LM)	21 (58.3%)				
IABP support	10 (19.2%)				
IVUS guidance	16 (30.7%)				
Complete revascularization	41 (78.8%)				
Procedural success	52 (100%)				



Clinical outcome (n=52)				
Follow-up period (months)	28.17+18.46			
Death	0 (0%)			
Myocardial infarction	0 (0%)			
Stroke	0 (0%)			
Repeat revascularization	5 (9.61%)			
PCI	5 (9.61%)			
CABG	0 (0%)			
Left main re-PCI	4 (7.69%)			
Stent Thrombosis	0 (0%)			
MACE	5 (9.61%)			



Updated 2011 ACC/AHA/SCAI Guidelines for ULMCA Stenosis






Percutaneous Coronary Intervention vs. Coronary Artery Bypass Graft Surgery for Unprotected Left Main Coronary Artery Disease in the Drug-Eluting Stents Era

An Aggregate Data Meta-Analysis of 11,148 Patients –

Mahboob Alam, MD; Henry D. Huang, MD; Saima A. Shahzad; Biswajit Kar, MD; Salim S. Virani, MD; Paul A. Rogers, MD; David Paniagua, MD; Biykem Bozkurt, MD; Igor Palacios, MD; Neal S. Kleiman, MD; Hani Jneid, MD

www.e-Cardio.gr



12-month major adverse cardiac and cerebrovascular events (MACCE)

PCI (DES) CABG Odds Ratio **Odds Ratio** Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI M-H, Random, 95% CI Year Sanmartin et al. (2007) 96 10 27 245 7.0% 0.94 [0.44, 2.02] 2007 Hsu et al. 0.13 [0.02, 1.13] 39 1.4% 2008 20 11 Makikallio et al. 0.44 [0.17, 1.16] 2008 49 238 5.1% 49 Wu et al. (2008) Not estimable 2008 0 0 0 16 52 53 Buszman et al. (RCT) 13 6.1% 1.37 [0.58, 3.23] 2008 White et al. 15 67 10 67 5.9% 1.64 [0.68, 3.98] 2008 Buszman et al. 63 18 75 5.6% 0.46 [0.19, 1.15] 2009 23 94 9.2% Cheng et al. 216 1.93 [1.06, 3.54] 2009 31 Ghenim et al. 15 105 14 106 6.9% 1.10 [0.50, 2.40] 2009 22 131 31 245 9.4% 1.39 [0.77, 2.52] 2010 Wu et al. 56 357 348 12.5% 1.19 [0.78, 1.81] 2010 Morice et al. (2010) 47 Kang et al. 49 205 32 257 11.1% 2.21 [1.35, 3.61] 2010 Park et al. (PRE-COMBAT) 300 300 9.2% 26 20 1.33 [0.72, 2.44] 2011 45 475 24 335 10.7% 1.36 [0.81, 2.27] 2011 Park et al.(PRECOMBAT Rg) Total (95% CI) 2014 2524 100.0% 1.22 [0.94, 1.58] Total events 291 327 Heterogeneity: $Tau^2 = 0.09$; $Chi^2 = 21.77$, df = 12 (P = 0.04); $I^2 = 45\%$ 0.01 0.1 100 Test for overall effect: Z = 1.50 (P = 0.13) Favours PCI Favours CABG



Non-fatal stroke at 12-months follow-up.


PCI (DES) CABG Odds Ratio Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl M-H, Random, 95% CI Year Sanmartin et al. (2007) 96 0 2 245 3.6% 0.50 [0.02, 10.61] 2007 2 39 3.5% 2008 Hsu et al. 20 0.37 [0.02, 7.99] 0 52 2008 Buszman et al. (RCT) 2 53 3.6% 0.20 [0.01, 4.19] Makikallio et al. 49 12 238 4.1% 0.18 [0.01, 3.14] 2008 Buszman et al. 63 6 75 4.0% 0.08 [0.00, 1.52] 2009 514 33.5% 0.32 [0.12, 0.88] 2009 Montalescot et al. 612 18 Morice et al. (2010) 357 348 7.8% 0.11 [0.01, 0.84] 2010 205 257 13.7% 0.31 [0.06, 1.46] 2010 Kang et al. 107 142 6.4% Chieffo et al. 0.44 [0.04, 4.26] 2010 95 192 8.2% 0.07 [0.01, 0.56] 2011 Rittger et al. 24 Boudriot et al. 100 101 3.6% 0.20 [0.01, 4.18] 2011 475 335 4.3% 0.70 [0.04, 11.31] 2011 Park et al. (PRECOMBAT Rg) Park et al. (PRE-COMBAT) 300 300 3.6% 0.20 [0.01, 4.16] 2011 Total (95% CI) 2433 2937 100.0% 0.25 [0.14, 0.44] Total events 11 91 Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 4.28$, df = 12 (P = 0.98); $I^2 = 0\%$ n n1 Test for overall effect: Z = 4.75 (P < 0.00001) Favours PCI Favours CABG




Repeat revascularization at 12-months follow-up.

	PCI (DI	ES)	CAB	G	Odds Ratio			Odds Ratio	
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% CI	Year	M-H, Random, 95% CI	
Sanmartin et al. (2007)	5	96	2	245	2.7%	6.68 [1.27, 35.02]	2007		
Hsu et al.	0	20	2	39	0.9%	0.37 [0.02, 7.99]	2008		
Buszman et al. (RCT)	15	52	5	53	4.9%	3.89 [1.30, 11.68]	2008	/ \	
Makikallio et al.	2	49	4	238	2.5%	2.49 [0.44, 13.99]	2008	/	
Wu et al. (2008)	9	56	1	56	1.8%	10.53 [1.29, 86.21]	2008		
Ghenim et al.	14	105	1	106	1.9%	16.15 [2.08, 125.24]	2009	/ — 	
Buszman et al.	5	63	3	75	3.2%	2.07 [0.47, 9.02]	2009	/ 	
Cheng et al.	13	94	3	216	4.0%	11.40 [3.16, 41.03]	2009	/ \	
Montalescot et al.	66	514	45	612	10.9%	1.86 [1.25, 2.77]	2009		
Kang et al.	35	205	10	257	7.6%	5.09 [2.45, 10.55]	2010		
Chieffo et al.	21	107	8	142	6.5%	4.09 [1.73, 9.65]	2010		
Morice et al. (2010)	43	357	23	348	9.6%	1.94 [1.14, 3.29]	2010	 -	
Park et al.(MAIN-COMPARE)	55	784	6	690	6.6%	8.60 [3.68, 20.10]	2010		
Wu et al.	15	131	8	245	6.3%	3.83 [1.58, 9.29]	2010		
Boudriot et al.	14	100	6	101	5.5%	2.58 [0.95, 7.01]	2011	 	
Park et al. (ASAN-MAIN)	7	176	2	219	2.9%	4.49 [0.92, 21.91]	2011	\	
Park et al. (PRE-COMBAT)	18	300	10	300	7.0%	1.85 [0.84, 4.08]	2011	\ +- /	
Rittger et al.	10	95	4	192	4.4%	5.53 [1.69, 18.13]	2011	\ — /	
Park et al. (PRECOMBAT Rg)	29	475	4	335	5.1%	5.38 [1.87, 15.45]	2011	\ — /	
Tamburino et al.	18	222	6	361	5.9%	5.22 [2.04, 13.36]	2011	\ /	
Total (95% CI)		4001		4830	100.0%	3.72 [2.75, 5.03]		•	
Total events	394		153						
Heterogeneity: Tau ² = 0.18; Chi		df= 19		2); I²=	44%				
Test for overall effect: Z = 8.49 (-		-/1	- ,			0.01 0.1 1 10 100 Favours PCI Favours CABG	







At 5 years, overall MACCE in the PCI group was comparable with CABG (31.0% CABG vs 36.9% PCI)













Joint ESC/EACTS Guidelines for Myocardial Revascularization 2010

4.1 Patient Information

Patient information needs to be objective and unbiased, patient orientated, evidence based, up-to-date, reliable, understandable, accessible, relevant and consistent with legal requirements. Informed consent requires transparency, especially if there is controversy about the indication for a particular intervention. Specialty bias and self-referral should not interfere with the process.

4.2 Multidisciplinary decision making (Heart Team)


The creation of a Heart Team serves the purpose of a balanced multidisciplinary decision process. Standard protocols compatible with the current Guidelines may be used to avoid the systematic need for case-by-case review of all diagnostic angiograms.

	Class	Level
It is recommended that patients be adequately informed about the potential benefits and short- and long-term risks of a revascularisation procedure. Enough time should be spared for informed decision making.	1	O
The appropriate revascularisation strategy in patients with MVD should be discussed by the Heart Team.	1	0



The meaning of HEART TEAM

The Heart Team







It is practical as the Heart Team...

Advantages reported in the literature

- ...improves (consistent) decision (making more accurate according to guidelines)
- ... Team has more knowledge than an individual
- ...Increases physician and patient wellbeing
- ...Higher ratings of patients' experience of care
- ...Physicians "share the burden"
- ...Improves outcomes
- ...Liability

But remember "Medicine is not a democracy"



Patient information and consent



When asked, most patients will prefer the less invasive PCI over surgery



How do we consent suitable patients?

"While the guidelines do not give left main stenting the highest recommendation and while most doctors are traditionally inclined to send patients such as yourself for bypass surgery, published evidence suggests similar survival rates with bypass and stent procedures...Your risk of stroke is definitely 4-5 fold lower with stent procedure, but you do have a higher risk of a repeat procedure due to stent renarrowing.

In my opinion a very reasonable option for you is ..."



CASE 1 Choice of the HEART TEAM





CASE 1

- 48 y.o. male.
- Risk factors for IHD:

 Hypertension


 Dyslipidaemia

 Smoker.
- Recent hospitalization for unstable angina




Critical stenosis at the ostium of left main










CASE 2 Patient's willingness





CASE 2

- 60 y.o. male.
- Risk factors for IHD:

Hypertension
Dyslipidaemia
ex-smoker

- In June 2006, underwent coronary artery bypass grafting for left main and three vessel disease.


LIMA - LAD

RIMA – Ramus intermediate

SVG - RCA



14 months later, presented with unstable angina






•re- do CABG?

- •Logistic EUROSCORE: 2.37.
- Patient unwilling to undergo surgery for a second time.
- *PCI?*
- •SYNTAX score: 47.5.
- Informed consent.



The patient remains asymptomatic 48 months after the 2nd PCI.





CASE 3 The inoperable patient







CASE 3

- 87 y.o. male with unstable angina (repeated hospitalizations)
- Risk factors for IHD:
 Hypertension
 Dyslipidaemia
 ex-smoker.
- In the last year 2 PCIs in LAD, Cx and OM1 in another hospital








Cx: Severe lesion at the ostium (restenosis, Logistic Euroscore 82.76 severe calcification)

OM1: Total occlusion (restenosis)




RCA: Total occlusion EF 25-30%.

SYNTAX score: 38.

Informed consent.





CASE 4

Fighting with a catastrophe. The only option?





CASE 4

- A 42 years old caucasian woman
- •No any previous medical history or any risk factors for coronary artery disease.
- •Presented to a district general hospital, with no cardiac catheter laboratory facilities, with acute anterior MI, complaining about a sudden-onset substernal chest pain lasting for the past 2h.
- Thrombolytic treatment was started immediately, with regression of the angina and almost normalization of the ECG changes.




On the eighth in hospital day, the patient suffered another episode of substernal chest pain, with hypotension and signs of left ventricular heart failure.





Spontaneous Left Main dissection







The patient remained asymptomatic at 3 months follow up and a MSCT coronary angiography showed the absence of re-stenosis



Hospital discharge on day 8.
Echocardiography at 1 month: ejection fraction was 35% with a moderate mitral regurgitation.



The patient remained asymptomatic at 3 months follow up and a MSCT coronary angiography showed the absence of re-stenosis

